As Advair generic hits, GSK looks to oncology to spur growth alongside Shingrix, HIV
admin 6th February 2019 Uncategorised 0GlaxoSmithKline had several years to prepare for the U.S. generic assault on its respiratory blockbuster Advair, offering discounts and rolling out new therapies to stay in the game. And now that the day has finally come, while sales are expected to decline, attention has shifted to rebuilding an interest in oncology.
More: As Advair generic hits, GSK looks to oncology to spur growth alongside Shingrix, HIV
Source: fierce